| Literature DB >> 32854428 |
Raquel Hernáez-Moya1, Sheyla González2, Arantza Urkaregi3, Jose Ignacio Pijoan4, Sophie X Deng2, Noelia Andollo1.
Abstract
Transplantation of human cultured limbal epithelial stem/progenitor cells (LESCs) has demonstrated to restore the integrity and functionality of the corneal surface in about 76% of patients with limbal stem cell deficiency. However, there are different protocols for the expansion of LESCs, and many of them use xenogeneic products, being a risk for the patients' health. We compared the culture of limbal explants on the denuded amniotic membrane in the culture medium-supplemental hormone epithelial medium (SHEM)-supplemented with FBS or two differently produced human sera. Cell morphology, cell size, cell growth rate, and the expression level of differentiation and putative stem cell markers were examined. Several bioactive molecules were quantified in the human sera. In a novel approach, we performed a multivariate statistical analysis of data to investigate the culture factors, such as differently expressed molecules of human sera that specifically influence the cell phenotype. Our results showed that limbal cells cultured with human sera grew faster and contained similar amounts of small-sized cells, higher expression of the protein p63α, and lower of cytokeratin K12 than FBS cultures, thus, maintaining the stem/progenitor phenotype of LESCs. Furthermore, the multivariate analysis provided much data to better understand the obtaining of different cell phenotypes as a consequence of the use of different culture methodologies or different culture components.Entities:
Keywords: cell therapy; explants culture; human amniotic membrane (HAM); human serum (HS); limbal epithelial stem/progenitor cells (LESC); limbal stem cell deficiency (LSCD); multivariate statistical analysis; partial least squares discriminant analysis (PLS-DA); principal component analysis (PCA) combined with clusters analysis; serum derived from plasma rich in growth factors (s-PRGF); xenogeneic-free cell expansion
Mesh:
Substances:
Year: 2020 PMID: 32854428 PMCID: PMC7503296 DOI: 10.3390/ijms21176132
Source DB: PubMed Journal: Int J Mol Sci ISSN: 1422-0067 Impact factor: 5.923
Figure 1LESCs cultured following the gold standard or explants culture methodologies with FBS or human HS and s-PRGF sera: (A) Phenotype of cell cultures; (B) Percentage of cells corresponding to each cell size; (C) Cell growth rate represented as the number of cell duplications per day. * Indicates significant differences between the gold standard culture and the indicated treatment. (* p < 0.05). Scale bar in phase-contrast microscopy images, 100 micrometers. LESCs: limbal epithelial stem/progenitor cells; FBS: fetal bovine serum; HS: human serum; s-PRGF: serum derived from plasma rich in growth factors.
Figure 2Protein expression profiles of several cell markers in LESCs obtained from explants and gold standard cultures treated with FBS or two different human sera: (A) Double immunostaining for K14 (green) and K12 (red) cytokeratins; (B) Immunostaining for p63α; (C) Percentage of K14 and K12 positive cells; (D) Percentage of p63α bright cells. *** Indicates significant differences between the gold standard culture and all the other treatments (p < 0.001), and φ between FBS and the indicated treatment (p < 0.05). Scale bar for fluorescence images, 100 micrometers.
Figure 3Relative mRNA expression of several cell markers in LESCs obtained from explants and gold standard cultures treated with FBS or two different human sera. * Indicates significant differences between the gold standard culture and the indicated treatments, and φ between the FBS and the indicated treatments. (* p < 0.05; ** p < 0.01) (φ p < 0.05; φφ p < 0.01).
The concentration of growth factors and other molecules in two different pools of the human blood derivatives—HS and s-PRGF.
|
|
|
|
|
|
|
|
|
|
| HS | 1 | 277.20 ± 0 | 59.06 ± 10.76 | 81.25 ± 0 | 24.38 ± 0.59 | 18.89 ± 1.53 | 5.12 ± 2.34 | 179.06 ± 5.31 |
| 2 | 709.76 ± 0 | 141.11 ± 13.59 | 123.0 ± 0 | 56.39 ± 6.92 | 19.31 ± 2.53 | 6.83 ± 0.75 | 280.66 ± 16.42 | |
| Mean ± SD | 493.48 ± 305.86 | 100.08 ± 48.42 | 109.08 ± 24.1 | 40.39 ± 18.91 | 19.10 ± 1.72 | 5.98 ± 1.73 | 229.86 ± 59.5 | |
| s-PRGF | 1 | 199.24 ± 12.71 | 28.01 ± 6.95 | 39.77 ± 0 | 21.50 ± 0.57 | 22.81 ± 2.83 | 5.66 ± 0.80 | 281.24 ± 233.04 |
| 2 | 544.48 ± 199.94 | 60.80 ± 0.04 | 59.47 ± 0 | 42.56 ± 6.53 | 19.53 ± 5.75 | 9.13 ± 1.08 | 112.43 ± 17.04 | |
| Mean ± SD | 371.85 ± 230.46 | 44.4 ± 19.35 | 49.62 ± 13.93 | 32.03 ± 12.73 | 21.17 ± 4.16 | 7.40 ± 2.15 | 196.83 ± 166.43 | |
|
|
|
|
|
|
|
|
|
|
| HS | 1 | 58.82 ± 11.12 | 0.00 ± 0 | 4.11 ± 2.43 | 60.41 ± 26.88 | 3.98 ± 0.49 | 55.21 ± 6.97 | 20.35 ± 0.31 |
| 2 | 112.18 ± 2.73 | 1.06 ± 0.08 | 10.19 ± 0.84 | 30.66 ± 7.95 | 2.47 ± 1.80 | 22.67 ± 9.07 | 11.34 ± 1.92 | |
| Mean ± SD | 85.5 ± 31.51 | 0.53 ± 0.61 | 7.15 ± 3.81 | 45.53 ± 23.6 | 3.23 ± 1.39 | 38.94 ± 19.91 * | 15.84 ± 5.32 * | |
| s-PRGF | 1 | 91.72 ± 11.28 | 0.00 ± 0 | 10.62 ± 3.31 | 42.53 ± 10.89 | 1.38 ± 0.03 | 0.00 ± 0 | 3.40 ± 0.39 |
| 2 | 31.11 ± 2.49 | 0.95 ± 0.22 | 11.54 ± 0.02 | 49.87 ± 31.75 | 5.44 ± 0 | 11.98 ± 0 | 1.25 ± 0.77 | |
| Mean ± SD | 61.41 ± 35.62 | 0.47 ± 0.56 | 11.08 ± 1.99 | 46.2 ± 19.84 | 3.41 ± 2.35 | 5.99 ± 6.91 | 2.32 ± 1.34 |
* Statistically significant differences between human serum (HS) and serum derived from plasma rich in growth factors (s-PRGF) (p < 0.05). Epidermal growth factor (EGF); hepatocyte growth factor (HGF); fibroblast basic growth factor (FGFb); keratocyte growth factor (KGF); platelet-derived growth factor AB (PDGF-AB); transforming growth factor-beta 1 (TGF-β1); vascular endothelial growth factor (VEGF); interferon-gamma (IFNγ); tumor necrosis factor-alpha (TNFα); nerve growth factor (NGF); insulin-like growth factor-1 (IGF-1); glial cell line-derived neurotrophic factor (GDNF); and substance P (SP).
Correlations of variables associated with cells cultured with human sera, between them, and with respect to human sera’s growth factors and molecules.
| <12 μm | 12–20 μm | >20 μm | Duplication Time | ICC K14 | ICC K12 | ICC ΔNp63α | PCR | PCR | PCR | PCR | PCR | PCR | EGF | HGF | FGFb | KGF | PDGF-AB | TGF-β | VEGF | Fibronectin | IFN-γ | TNF-α | NGF | IGF-1 | GDNF | SP | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||||||||||||||||||||
|
| 92% | 66% | |||||||||||||||||||||||||
|
|
| ||||||||||||||||||||||||||
|
| −80% | −75% | 75% | ||||||||||||||||||||||||
|
| 63% | 63% | 63% | 63% | −58% | 58% | |||||||||||||||||||||
|
| −66% | ||||||||||||||||||||||||||
|
| −74% | ||||||||||||||||||||||||||
|
| 60% | ||||||||||||||||||||||||||
|
|
|
| |||||||||||||||||||||||||
|
| |||||||||||||||||||||||||||
|
|
|
| 62% | ||||||||||||||||||||||||
|
|
|
| −65% | 73% | 65% | −73% | −65% | ||||||||||||||||||||
|
|
| −67% |
* Statistically significant correlations (* p < 0.05; ** p < 0.01; *** p < 0.001). ICC: Immunocytochemistry; PCR: polymerase chain reaction.
Correlations between human sera’s growth factors and molecules.
| EGF | HGF | FGFb | KGF | PDGF-AB | TGF-β | VEGF | Fibronectin | IFN-γ | TNF-α | NGF | IGF-1 | GDNF | SP | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
| 100% | 80% | 100% | 60% | 95% | |||||||||
|
|
| 80% | 100% | 60% | 95% | |||||||||
|
|
|
| 80% | −80% | −60% | 80% | 60% | |||||||
|
|
|
|
| 60% | 95% | |||||||||
|
|
| 80% | −100% | −80% | ||||||||||
|
|
|
|
| 0.74% | 80% | −80% | ||||||||
|
| 80% | −60% | −100% | |||||||||||
|
|
| −80% | −80% | |||||||||||
|
|
|
|
|
| −63% | |||||||||
|
|
|
|
| −80% | −100% | |||||||||
|
|
|
|
| 60% | −63% | |||||||||
|
|
|
|
| |||||||||||
|
|
|
|
| 80% | ||||||||||
|
|
|
|
|
|
|
|
* Statistically significant correlations (* p < 0.05; ** p < 0.01; *** p < 0.001).
Figure 4Representation of all samples in three components obtained by (A) Principal component analysis (PCA); (B) Partial least squares discriminant analysis (PLS-DA). Colors indicate treatments. Cultures following the gold standard culture methodology are separated from cultures following explants culture methodology.
Figure 5Representation of samples treated with human sera in three components obtained by PCA analysis. Colors indicate (A) treatments; (B) group of cornea-HAM (human amniotic membrane). Samples were classified mainly by cornea-HAM and not by treatment.
Figure 6Representation of samples treated with human sera in three components obtained by PCA analysis. The analysis also included as variables some molecules measured in sera (glial cell-derived neurotrophic factor (GDNF), substance P (SP), epidermal growth factor (EGF)). Colors indicate treatments. Samples were well classified by treatment.
Characteristics of each cluster of the hierarchical 12-cluster analysis. For each cluster, variables of cultured cells (expression of several proteins (ICC) or mRNA (PCR)), as well as the content of the human sera, in growth factors and signaling molecules are shown.
| s-PRGF1 | s-PRGF2 | HS1 | HS2 | |
|---|---|---|---|---|
|
|
|
|
|
|
| Variables of cultured cells | − ICC ΔNp63α | +++ ICC ΔNp63α | +++ PCR | − PCR |
| −−− PCR | ++ Size 3 | + PCR | −− PCR | |
| −− PCR | −−− PCR | |||
| −−− PCR | ||||
| Content of the sera in GFs | +++ PDGF | +++ TGF | +++ GDNF, SP | +++ HGF, FGFb |
| ++ VEGF | ++ IGF-1 | ++ NGF | ++ KGF, EGF | |
| − SP | −− FN, VEGF | −−− TNF | −− NGF | |
| −− EGF, GDNF | ||||
| −−− IGF-1 | ||||
|
|
|
|
|
|
| Variables of cultured cells | + PCR | +++ Size 1 | +++ PCR | +++ PCR |
| −−− PCR | ++ PCR | ++ PCR | ++ PCR | |
| + PCR | − Size1 | + PCR | ||
| −− PCR | −−−Size 2 | |||
| Content of the sera in GFs | ++ PDGF | ++ TGF-β, IGF-1 | +++ GDNF, SP | +++ HGF, FGFb |
| − EGF, GDNF | −− FN, VEGF | ++ NGF | ++ KGF, EGF | |
| −− IGF-1 | −−− TNF | −− NGF | ||
|
|
|
|
|
|
| Variables of cultured cells | +++ PCR | +++ PCR | − PCR | − PCR |
| ++ ICC ΔNp63α, Size 2 | −−− PCR | −−− PCR | −−− PCR | |
| − Size 3 | ||||
| Content of the sera in GFs | ++ PDGF | ++ TGF-β, IGF-1 | + FGFb | + FGFb |
| − IGF-1 | −− FN, VEGF |
Positive (+) and negative (−) statistically significant differences between cluster mean and global mean: + (p < 0.05), ++ (p < 0.01) and +++ (p < 0.001); − (p < 0.05), −− (p < 0.01) and −−− (p < 0.001). Cluster 4 has been excluded from the table because it only contains two samples corresponding to two different treatments. GF: growth factors; Size 1: cell size < 12 µm; Size 2: 12–20 µm; Size 3: cell size > 20 µm.